

Special Issue

IgE in Autoimmunity

Message from the Guest Editor

Autoantibodies in autoimmune diseases are often described as major pathogenic factors. Depending on their isotype and/or their specificity, these autoantibodies can participate to either protective or deleterious pathophysiological mechanisms in various autoimmune diseases. IgE is well recognized as a pathogenic factor in IgE-mediated allergic diseases. Research from the last couple of decades could also demonstrate their key role in some autoimmune diseases. Some studies have identified total IgE and autoreactive IgE as involved in pathophysiology, as strong diagnostic and prognostic biomarkers, and/or as valuable therapeutic targets. Indeed, anti-IgE monoclonal antibody Omalizumab was tested in various autoimmune diseases and often showed promising therapeutic value. This Special Issue of *Antibodies* focuses on some autoimmune diseases where autoantibodies of the IgE isotype have been evidenced, with specific emphasis on different pathogenic mechanisms (specificity, immune complexes, cell types involved in their pathogenic effects, etc.), potential therapeutic targeting, and critical information that can be derived from the study of IgE autoantibodies.

Guest Editor

Dr. Nicolas Charles

Centre de Recherche sur l'Inflammation-INSERM UMRS1149-CNRS ERL8252-Université de Paris; Team Basophils, Mast cells and Immunopathology; Laboratoire d'excellence Inflammex-DHU Fire-Faculté de Médecine Site Bichat, 16 rue Henri Huchard, Paris, France

Deadline for manuscript submissions

closed (30 November 2020)



Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 7.1
Indexed in PubMed



mdpi.com/si/38455

Antibodies
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)





Antibodies

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 7.1
Indexed in PubMed



[mdpi.com/journal/
antibodies](https://mdpi.com/journal/antibodies)



About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)